Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy

被引：21

作者：

Mori S. ^{[1
]}

Kishimoto H. ^{[1
]}

Tauchi K. ^{[1
]}

Higuchi K. ^{[2
]}

机构：

[1] Department of Surgery, Aizawa Hospital, Matsumoto, Nagano 390-8510

[2] Department of Pathology, Aizawa Hospital, Nagano

来源：

Gastric Cancer | 2006年 / 9卷 / 2期

关键词：

Advanced gastric cancer; Complete response; Neoadjuvant chemotherapy; S-1;

D O I：

10.1007/s10120-005-0358-z

中图分类号：

学科分类号：

摘要：

Single-agent or combined chemotherapy with the novel oral fluoropyrimidine anticancer drug, S-1 (TS-1), has been reported to be useful for the treatment of advanced gastric cancer. Here, we report a patient with advanced gastric cancer achieving a complete response (CR) after 2 weeks of administration of S-1 as neoadjuvant chemotherapy. A 78-year-old woman with epigastric pain was diagnosed as having advanced gastric cancer. S-1 was administered orally, at a dose of 50 mg twice a day every day for 2 weeks, followed by a 2-week drug-free period. No obvious adverse reactions occurred. Subsequently, the patient underwent distal partial gastrectomy with D2 lymph node dissection. Pathological examination indicated no remnant signet-ring cells in the excised specimen, no lymph node metastasis, and unnatural fibrosis in one of the No. 3 lymph nodes. The neoadjuvant chemotherapy induced a CR according to the Japanese classification of gastric carcinoma. © 2006 by International and Japanese Gastric Cancer Associations.

引用

页码：136 / 139

页数：3

共 17 条

[1]

Sakata Y., Ohtsu A., Hirokoshi N., Sugimachi K., Mitachi Y., Taguchi T., Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1∈M tegafur-0.4∈M gimestat-1∈M otastat potassium) in advanced gastric cancer patients, Eur J Cancer, 34, pp. 1715-20, (1998)

[2]

Koizumi W., Kurihara M., Nakano S., Hasegawa K., Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. for the S-1 Cooperative Gastric Cancer Study Group, Oncology, 58, pp. 191-7, (2000)

[3]

Sasaki T., Current topics of S-1 at the 74th Japanese Gastric Cancer Congress, Gastric Cancer, 6, pp. 9-12, (2003)

[4]

Kameyama H., Nashimoto A., Yabusaki H., Takii Y., Tsuchiya Y., Tanaka O., A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP therapy (in Japanese), Gan to Kagaku Ryoho (Jpn J Cancer Chemother), 30, pp. 1485-8, (2003)

[5]

Iwahashi M., Nakamori M., Tani M., Yamaue H., Sakaguchi S., Nakamura M., Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low-dose cisplatin: Report of a case, Oncology, 61, pp. 16-22, (2001)

[6]

Yamamoto Y., Kino Y., Ohara K., Onuma S., Asai K., Kobayashi T., A case report of advanced cardiac cancer showing a complete response to TS-1 as neoadjuvant chemotherapy (in Japanese), Gan to Kagaku Ryoho (Jpn J Cancer Chemother), 31, pp. 579-83, (2004)

[7]

Japanese classification of gastric carcinoma. 2nd English ed, Gastric Cancer, 1, pp. 10-24, (1998)

[8]

Japanese classification of gastric carcinoma. 2nd English edition. Response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria, Gastric Cancer, 4, pp. 1-8, (2001)

[9]

The General Rules for Gastric Cancer Study 13th Ed. (In Japanese), (1999)

[10]

Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators, Anticancer Drugs, 7, pp. 548-57, (1996)

← 1 2 →